These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 17623832)
21. Prognostic value of pre- and post-transplantation Ying Z; Mi L; Wang X; Zhang Y; Yang Z; Song Y; Wang X; Zheng W; Lin N; Tu M; Xie Y; Ping L; Zhang C; Liu W; Deng L; Zhu J Chin J Cancer Res; 2017 Dec; 29(6):561-571. PubMed ID: 29353979 [TBL] [Abstract][Full Text] [Related]
22. Pre-transplant (18)F-fluorodeoxyglucose positron emission tomography-based survival model in patients with aggressive lymphoma undergoing high-dose chemotherapy and autologous SCT. Akhtar S; Al-Sugair AS; Abouzied M; Alkadhi Y; Dingle M; Abdelsalam M; Soudy H; Darwish A; Eltigani A; Elhassan TA; Nabil-Ahmed M; Maghfoor I Bone Marrow Transplant; 2013 Apr; 48(4):551-6. PubMed ID: 22964592 [TBL] [Abstract][Full Text] [Related]
23. The value of complete remission according to positron emission tomography prior to autologous stem cell transplantation in lymphoma: a population-based study showing improved outcome. Noring K; Carlsten M; Sonnevi K; Wahlin BE BMC Cancer; 2021 May; 21(1):500. PubMed ID: 33947353 [TBL] [Abstract][Full Text] [Related]
24. Predictive value of early 18F-fluoro-deoxyglucose positron emission tomography in chemosensitive relapsed lymphoma. Schot B; van Imhoff G; Pruim J; Sluiter W; Vaalburg W; Vellenga E Br J Haematol; 2003 Oct; 123(2):282-7. PubMed ID: 14531910 [TBL] [Abstract][Full Text] [Related]
25. Are dynamic or fixed FDG-PET measures of disease of greater prognostic value in patients with relapsed/refractory diffuse large B-cell lymphoma undergoing autologous haematopoietic stem cell transplantation? Campbell BA; Brown R; Lambertini A; Hofman MS; Bressel M; Seymour JF; Wirth A; MacManus M; Dickinson M Br J Haematol; 2023 May; 201(3):502-509. PubMed ID: 37015002 [TBL] [Abstract][Full Text] [Related]
26. Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation. Becherer A; Mitterbauer M; Jaeger U; Kalhs P; Greinix HT; Karanikas G; Pötzi C; Raderer M; Dudczak R; Kletter K Leukemia; 2002 Feb; 16(2):260-7. PubMed ID: 11840293 [TBL] [Abstract][Full Text] [Related]
28. Prognostic Value of FDG PET/CT before Allogeneic and Autologous Stem Cell Transplantation for Aggressive Lymphoma. Ulaner GA; Goldman DA; Sauter CS; Migliacci J; Lilienstein J; Gönen M; Schöder H; Moskowitz CH; Zelenetz AD Radiology; 2015 Nov; 277(2):518-26. PubMed ID: 26035588 [TBL] [Abstract][Full Text] [Related]
29. Unifying the predictive value of pretransplant FDG PET in patients with lymphoma: a review and meta-analysis of published trials. Poulou LS; Thanos L; Ziakas PD Eur J Nucl Med Mol Imaging; 2010 Jan; 37(1):156-62. PubMed ID: 19727713 [TBL] [Abstract][Full Text] [Related]
30. Prognostic impact of pre-transplantation computed tomography and 67gallium scanning in chemosensitive diffuse large B cell lymphoma patients undergoing hematopoietic stem-cell transplantation. Escobar IG; Alonso PT; Barrigon DC; Perez-Simon JA; Mateos Manteca MV; San Miguel Izquierdo JF Ann Nucl Med; 2008 May; 22(4):251-60. PubMed ID: 18535875 [TBL] [Abstract][Full Text] [Related]
31. Powerful prognostic stratification by [18F]fluorodeoxyglucose positron emission tomography in patients with metastatic breast cancer treated with high-dose chemotherapy. Cachin F; Prince HM; Hogg A; Ware RE; Hicks RJ J Clin Oncol; 2006 Jul; 24(19):3026-31. PubMed ID: 16717291 [TBL] [Abstract][Full Text] [Related]
32. Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma. Schot BW; Zijlstra JM; Sluiter WJ; van Imhoff GW; Pruim J; Vaalburg W; Vellenga E Blood; 2007 Jan; 109(2):486-91. PubMed ID: 17003382 [TBL] [Abstract][Full Text] [Related]
33. Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma. Jerusalem G; Beguin Y; Fassotte MF; Najjar F; Paulus P; Rigo P; Fillet G Haematologica; 2000 Jun; 85(6):613-8. PubMed ID: 10870118 [TBL] [Abstract][Full Text] [Related]
34. Disease staging with positron emission tomography or gallium scanning and use of rituximab predict outcome for patients with diffuse large B-cell lymphoma treated with autologous stem cell transplantation. Alousi AM; Saliba RM; Okoroji GJ; Macapinlac HA; Hosing C; Korbling M; Samuels BI; Popat U; Kebriaei P; Anderlini P; Qazilbash MH; de Lima M; Giralt SA; Champlin RE; Khouri IF Br J Haematol; 2008 Sep; 142(5):786-92. PubMed ID: 18564354 [TBL] [Abstract][Full Text] [Related]
35. 18F-FDG PET for evaluation of the treatment response in patients with gastrointestinal tract lymphomas. Kumar R; Xiu Y; Potenta S; Mavi A; Zhuang H; Yu JQ; Dhurairaj T; Dadparvar S; Alavi A J Nucl Med; 2004 Nov; 45(11):1796-803. PubMed ID: 15534046 [TBL] [Abstract][Full Text] [Related]
36. Prognostic value of PET/CT in patients with lymphoma treated with autologous stem cell transplantation for relapsed/refractory or high risk disease. Stefani PM; Salvadori U; Gottardi M; Bissoli S; Chierichetti F; Gherlinzoni F Q J Nucl Med Mol Imaging; 2019 Mar; 63(1):62-67. PubMed ID: 26101430 [TBL] [Abstract][Full Text] [Related]
37. Positron emission tomography derived metrics in relapsed or refractory large B-cell lymphoma with residual disease before autologous stem cell transplant. Cherng HJ; Xu G; Feng L; Steiner R; Fayad L; Strati P; Nair R; Nastoupil LJ; Lee HJ; Neelapu SS; Flowers CR; Rodriguez M; Wang M; Hagemeister F; Pinnix CC; Ramdial J; Srour S; Nieto Y; Rezvani K; Champlin R; Kebriaei P; Westin J; Macapinlac HA; Shpall E; Ahmed S Br J Haematol; 2023 Jan; 200(1):35-44. PubMed ID: 36068929 [TBL] [Abstract][Full Text] [Related]